Rodney J. Hicks
YOU?
Author Swipe
View article: Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma Open
Oral ibrutinib (I) and venetoclax (V) demonstrate activity as monotherapy in marginal zone lymphoma (MZL), with low complete response (CR) rates. I+V has shown good clinical activity with acceptable tolerability in other malignancies. We c…
View article: Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study Open
Supplementary material
View article: AI-based Clinical Decision Support for Primary Care: A Real-World Study
AI-based Clinical Decision Support for Primary Care: A Real-World Study Open
We evaluate the impact of large language model-based clinical decision support in live care. In partnership with Penda Health, a network of primary care clinics in Nairobi, Kenya, we studied AI Consult, a tool that serves as a safety net f…
View article: Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity
Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity Open
View article: Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary Open
View article: Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience Open
View article: Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles Open
View article: Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting
Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting Open
True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (…
View article: A cutting-edge technology for the future of nuclear medicine
A cutting-edge technology for the future of nuclear medicine Open
View article: Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the <scp>European Neuroendocrine Tumor Society Advisory Board Meeting</scp> 2022 and the <scp>ENETS Theranostics Task Force</scp>
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the <span>European Neuroendocrine Tumor Society Advisory Board Meeting</span> 2022 and the <span>ENETS Theranostics Task Force</span> Open
Assessing the response to systemic therapy in neuroendocrine tumors (NET) is challenging since morphological imaging response is often delayed and not necessarily reflective of clinical benefit. Peptide receptor radionuclide therapy (PRRT)…
View article: High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography Open
We investigated a new PET/CT scanner (positron emission tomography/computed tomography) for detection of prostate cancer recurrence. This more sensitive scanner had a higher detection rate, particularly for patients with low PSA (prostate-…
View article: Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours
Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours Open
View article: Poor diagnostic performance of the melanin-binding tracer [18F]MEL050 in human melanoma indicates biological heterogeneity
Poor diagnostic performance of the melanin-binding tracer [18F]MEL050 in human melanoma indicates biological heterogeneity Open
Purpose Malignant melanoma is a highly lethal malignancy typically characterized by the expression of melanin, which is an attractive diagnostic and therapeutic target in these cancers because it is expressed in few other tissues. Followin…
View article: Total-Body PET/CT: Pros and Cons
Total-Body PET/CT: Pros and Cons Open
PET/CT devices with an axial field-of-view (FOV) of 1 m allow simultaneous imaging from the head to the upper thighs, the typical axial extent of many "whole-body" oncological studies acquired by moving a patient sequentially through a con…
View article: Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary
Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary Open
Genomics holds promise for precision treatment and identifying the primary tissue of origin (TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and diagnostic superiority of whole genome and transcriptome sequen…
View article: Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting
Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting Open
True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (…
View article: <sup>18</sup>F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology
<sup>18</sup>F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology Open
We evaluated the incidence and potential etiology of tracheobronchial uptake in patients being evaluated by 18F-DCFPyL PET/CT for prostate cancer (PCa). Methods: The study included a consecutive 100 PCa patients referred …
View article: International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation Open
Total metabolic tumor volume (TMTV) is prognostic in lymphoma. However, cutoff values for risk stratification vary markedly, according to the tumor delineation method used. We aimed to create a standardized TMTV benchmark dataset allowing …
View article: Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles Open
View article: Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions Open
In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both once daily. High complete remission (C…
View article: Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours Open
Purpose To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ 177 Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). Methods This study was part of a…
View article: Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms
Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms Open
Background Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective. Patients unsuitable for bilateral adrena…
View article: Issue Information
Issue Information Open
The CH icon indicates that continuing nursing education contact hours are available for this activity.G The Guideline icon identifies AORN guideline-related content that provides guidance in implementing specific AORN guidelines.A The Ambu…
View article: Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients
Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients Open
Background A recent randomised trial demonstrated [ 18 F]fluorodeoxyglucose positron-emission tomography in combination with low-dose CT (FDG-PET/CT), compared to standard of care computed tomography (CT) imaging, positively impacted antim…
View article: Evaluation of manual and automated approaches for segmentation and extraction of quantitative indices from [<sup>18</sup>F]FDG PET-CT images
Evaluation of manual and automated approaches for segmentation and extraction of quantitative indices from [<sup>18</sup>F]FDG PET-CT images Open
Utilisation of whole organ volumes to extract anatomical and functional information from computed tomography (CT) and positron emission tomography (PET) images may provide key information for the treatment and follow-up of cancer patients.…
View article: Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement Open
View article: Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis Open
Background: FDG-PET/CT used for immune checkpoint inhibitor (ICI) response assessment can incidentally identify immune-related adverse events (irAEs), including thyroiditis. This study aimed to correlate the time course of FDG-PET/CT evide…
View article: OP122 Economic Evidence To Support Expanding Use Of Existing Positron Emission Tomography Technology As A Diagnostic Tool For High-Risk Cancer Patients
OP122 Economic Evidence To Support Expanding Use Of Existing Positron Emission Tomography Technology As A Diagnostic Tool For High-Risk Cancer Patients Open
Introduction In Australia, 18F-fluorodeoxyglucose positron emission tomography with low-dose computed tomography (FDG-PET/CT) is currently only funded for cancer staging-related indications. A recent multicenter randomized trial demonstrat…
View article: Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis Open
Introduction Hypophysitis is reported in 8.5%–14% of patients receiving combination immune checkpoint inhibition (cICI) but can be a diagnostic challenge. This study aimed to assess the role of routine diagnostic imaging performed during t…
View article: P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT doses during chemoRT for NSCLC Correlates with Lymphocyte Decline
P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT doses during chemoRT for NSCLC Correlates with Lymphocyte Decline Open